A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Condition: Chemotherapy-induced Nausea and Vomiting
MeSH terms: Nausea; Vomiting
Intervention: fosnetupitant/ palonosetron; netupitant/palonosetron; dexamethasone
Intervention description: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination; oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination; Oral dexamethasone (12 mg)
Intervention MeSH terms: Dexamethasone; Palonosetron
Phase: Phase 3
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 404.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study
      assessing the safety and describing the efficacy of a single dose of intravenous (IV)
      fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral
      netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administered with oral
      dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer
      patients.
    

Eligibility criteria:

        Inclusion Criteria:

        Cycle 1:

        The following inclusion criteria must be checked prior to inclusion at Cycle 1:

          1. Patient read, understood and signed the written informed consent before any study
             related activity, agreeing to participate in the study and to comply with study
             requirements.

          2. Female patient of at least 8 years of age.

          3. Histologically or cytologically confirmed breast cancer, including recurrent or
             metastatic.

          4. Naïve to moderately or highly emetogenic antineoplastic agents.

          5. Scheduled to receive at least 4 consecutive cycles of an AC combination regimen.

             Notes:

               1. additional not emetogenic, minimally or low emetogenic antineoplastic agents are
                  permitted at any time after start of AC combination on Day 1.

               2. additional highly or moderately emetogenic antineoplastic agents are only allowed
                  on Day 1 after the start of AC combination, provided their administration is
                  completed within 6 hours from the start of the AC combination administration.

          6. ECOG Performance Status of 0 or 1.

          7. Patient shall be: a) of non-childbearing potential or b) of childbearing potential
             using reliable contraceptive measures and having a negative urine pregnancy test
             within 24 hours prior to dose of investigational product.

             Notes:

               1. Female patients of non-childberaring potential are defined as being in
                  post-menopausal state since at least 1 year; or having documented surgical
                  sterilization or hysterectomy at least 3 months before study participation.

               2. Reliable contraceptive measures include implants, injectables, combined oral
                  contraceptives, intrauterine devices, vasectomized partner or complete (long
                  term) sexual abstinence;

          8. Hematologic and metabolic status adequate for receiving a cycle of AC chemotherapy
             based on investigator's assessment.

          9. If the patient has a known hepatic or renal impairment, she may be enrolled in the
             study at the discretion of the Investigator.

         10. Able to read, understand, follow the study procedure and complete the patient diary.

        All inclusion criteria will be checked at screening visit (Visit 1 of Cycle 1); inclusion
        criteria 7 will be re-checked at Day 1 (Visit 2).

        Cycles 2 to 4:

        The following inclusion criteria must be checked prior to inclusion at each repeated cycle:

          1. Participation in the study during the next cycle of chemotherapy is considered
             appropriate by the Investigator and does not pose unwarranted risk to the patient.

          2. Scheduled to receive an AC chemotherapy regimen or AC chemotherapy together with other
             chemotherapies as defined in Inclusion criterion #5 for Cycle 1.

          3. Patient shall be: a) of non-childbearing potential or b) of childbearing potential
             using reliable contraceptive measures and having a negative urine pregnancy test
             within 24 hours prior to dosing of investigational product.

          4. Adequate hematologic and metabolic status for receiving a cycle of AC chemotherapy
             according to the Investigator's opinion.

        All inclusion criteria will be checked at screening visit (Visit 1); inclusion criterion #3
        will be re-checked at Day 1 (Visit 2).

        Exclusion Criteria:

        Cycle 1:

        The following exclusion criteria must be checked prior to inclusion at Cycle 1:

          1. Lactating patient.

          2. Current use of illicit drugs or current evidence of alcohol abuse.

          3. Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition
             to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 and up
             to Day 1 of Cycle 2.

          4. Received or is scheduled to receive radiation therapy to the abdomen or the pelvis
             within 1 week prior to the start of AC chemotherapy administration on Day 1 or between
             Days 1 to 5, inclusive.

          5. Any vomiting, retching, or nausea (grade 1 as defined by National Cancer Institute)
             within 24 hours prior to the start of AC chemotherapy administration on Day 1.

          6. Symptomatic primary or metastatic central nervous system (CNS) malignancy.

          7. Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial
             pressure, hypercalcemia, an active infection or any illness or medical conditions
             (other than malignancy) that, in the opinion of the Investigator, may confound the
             results of the study, represent another potential etiology for emesis and nausea
             (other than chemotherapy-induced nausea and vomiting [CINV]) or pose unwarranted risks
             in administering the study drugs to the patient.

          8. Known hypersensitivity or contraindication to 5 hydroxytryptamine type 3 (5-HT3)
             receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron,
             tropisetron, ramosetron), to dexamethasone, or to neurokinin-1 (NK1) receptor
             antagonists (e.g., aprepitant, rolapitant).

          9. Known contraindication to the IV administration of 50 mL 5% glucose solution.

         10. Participation in a previous clinical trial involving IV fosnetupitant or oral
             netupitant administered alone or in combination with palonosetron.

         11. Any investigational drugs taken within 4 weeks prior to Day 1, and/or is scheduled to
             receive any investigational drug (other than those planned by the study protocol)
             during the present study.

         12. Systemic corticosteroid therapy within 72 hours prior to the start of AC chemotherapy
             administration on Day 1, except the dexamethasone provided as additional study drug.
             However, topical and inhaled corticosteroids are permitted.

         13. Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy
             during the study participation.

         14. Other than as administered as part of the study protocol, any medication with known or
             potential antiemetic activity within 24 hours prior to the start of AC chemotherapy
             administration on Day 1, including:

               -  5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron,
                  tropisetron, ramosetron, palonosetron)

               -  NK1 receptor antagonists (e.g., aprepitant, fosaprepitant, rolapitant or any
                  other new drug of this class)

               -  benzamides (e.g., metoclopramide, alizapride)

               -  phenothiazines (e.g., prochlorperazine, promethazine, fluphenazine, perphenazine,
                  thiethylperazine, chlorpromazine)

               -  benzodiazepines (except if the subject is receiving such medication for sleep or
                  anxiety and has been on a stable dose for at least seven days prior to Day 1).

               -  butyrophenones (e.g., haloperidol, droperidol)

               -  anticholinergics (e.g., scopolamine, with the exception of inhaled
                  anticholinergics for respiratory disorders, e.g., ipratropium bromide)

               -  antihistamines (e.g., cyclizine, hydroxyzine, diphenhydramine, chlorpheniramine)

               -  domperidone

               -  mirtazapine

               -  olanzapine

               -  prescribed cannabinoids (e.g., tetrahydrocannabinol or nabilone)

               -  Over The Counter (OTC) antiemetics, OTC cold or OTC allergy medications.

         15. Scheduled to receive any strong or moderate inhibitor of CYP3A4 during the efficacy
             assessment period (Day 1 to Day 5, inclusive) or its intake within 1 week prior to Day
             1.

         16. Scheduled to receive any CYP3A4 inducer during the efficacy assessment period (Day 1
             to Day 5, inclusive) or its intake within 4 weeks prior to Day 1, with the exception
             of corticosteroids (for which exclusion criterion #12 applies).

         17. History or predisposition to cardiac conduction abnormalities, except for incomplete
             right bundle branch block.

         18. History of risk factors for Torsades de Pointes (heart failure, hypokalemia, family
             history of Long QT Syndrome).

         19. Severe or uncontrolled cardiovascular diseases, including myocardial infarction within
             3 months prior to Day 1, unstable angina pectoris, significant valvular or pericardial
             disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure
             (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial
             hypertension.

        All exclusion criteria with the exception of criteria #5, #12, and #14 will be checked at
        screening visit (Visit 1). Exclusion criteria #5, #12, and #14 will be checked at Day 1
        (Visit 2) only.

        Exclusion criteria #3, #4, #7, #11, #13, #15, and #16 need to be re-checked at Day 1 (Visit
        2).

        Cycles 2 to 4:

        The following exclusion criteria must be checked prior to inclusion at each repeated cycle:

          1. Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition
             to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 of
             current cycle and up to Day 1 of the next cycle.

          2. Active infection or uncontrolled disease that may pose unwarranted risks in
             administering the study drugs to the patient.

          3. Started any of the prohibited medications.

          4. Any vomiting, retching, or nausea (grade ≥ 1 as defined by National Cancer Institute)
             within 24 hours prior to the start of AC chemotherapy administration on Day 1.

          5. Received or is scheduled to receive radiation therapy to the abdomen or the pelvis
             within 1 week prior to the start of AC chemotherapy administration on Day 1 or between
             Days 1 to 5.

          6. Symptomatic primary or metastatic CNS malignancy.

          7. Any illness or medical condition that, in the opinion of the investigator, may
             confound the results of the study or pose unwarranted risks in administering the
             investigational product or dexamethasone to the patient.

        All exclusion criteria, with exception of criterion #4, will be checked at screening visit
        (Visit 1). Exclusion criterion #4 will be checked at Day 1 (Visit 2) only. Exclusion
        criteria #2, #3 and #5 need to be re-checked at Day 1 (Visit 2).